olivLaw · US equity research
Caris Life Sciences, Inc. CAI
Services-Medical Laboratories · SIC 8071 · Vertical: Services-Medical Laboratories (SIC 8071)
Caris Life Sciences develops and commercializes precision medicine profiling in oncology, combining next-generation sequencing, artificial intelligence and large clinico-genomic datasets. The company reported strong revenue growth in 2026, and recent launches of early detection and prognostic tests extend its offering beyond traditional tissue testing. Total revenue was 263.7 million USD in the second quarter of 2026, and 2026 guidance sits between 1.03 and 1.04 billion USD.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Caris Life Sciences, Inc. (CAI) stock was 33.22 USD (+1.13% on the day), with market capitalisation 9.5 bn USD, P/E 97.6 on diluted EPS of 0.34 USD over the last 12 months, beta 1.41, 52-week range 14.55–36.14 USD. Latest reported quarter (Q3 2026): revenue of 275.4 m USD (+27.0% YoY), net income of 15.3 m USD (−37.3% YoY), diluted EPS 0.05 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 56.8
- strong (55–70)
- Bollinger (20, 2)
- 27.75 – 35.96
- in the upper half of the band · %B 0.67 · band width 25.7%
- SMA 50 / 200
- 29.52 / 21.67
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 1.31 / 1.37
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +9.3% | −1.1% | +10.4 pp | — |
| 3 months | +101.9% | −0.5% | +102.4 pp | — |
| 6 months | +73.7% | +4.4% | +69.3 pp | — |
| Year to date | +23.1% | +12.3% | +10.8 pp | — |
| 1 year | +6.5% | +13.5% | −7.0 pp | −3.1% |
| 3 years | unavailable | +76.4% | unavailable | +69.6% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 129.9 m | 120.9 m | 181.4 m | 216.8 m | 292.9 m | 216.2 m | 263.7 m | 275.4 m |
| Research & development | 27.1 m | 23.1 m | 25.0 m | 21.6 m | 31.8 m | 31.3 m | 32.4 m | 33.8 m |
| Operating income | -37.0 m | -58.0 m | -18.0 m | 32.6 m | 88.4 m | 5.3 m | 26.9 m | 19.3 m |
| Depreciation & amortisation | 9.1 m | 7.0 m | 6.4 m | 4.9 m | 4.3 m | 5.1 m | 6.5 m | 6.6 m |
| Interest expense | 13.3 m | 12.8 m | 19.2 m | 13.5 m | 11.4 m | 12.8 m | 9.2 m | 9.2 m |
| Pre-tax income | -36.9 m | -102.6 m | -71.8 m | 24.3 m | 82.0 m | -644.0 k | -614.0 k | 16.9 m |
| Income tax | 0 | 0 | 0 | 0 | 0 | -134.0 k | 23.0 k | 1.6 m |
| Net income | -36.9 m | -102.6 m | -71.8 m | 24.3 m | 82.0 m | -510.0 k | -637.0 k | 15.3 m |
| Diluted EPS | -1.04 ≈ | -3.57 | -7.97 | 0.08 | 0.29 ≈ | 0.00 | 0.00 | 0.05 |
| Operating cash flow | -38.9 m | -31.3 m | 7.3 m ≈ | 62.4 m ≈ | 44.8 m | 32.9 m | 28.5 m ≈ | -22.2 m ≈ |
| Capex | 2.3 m | 2.7 m | 1.4 m ≈ | 7.1 m ≈ | 5.1 m | 10.3 m | 22.1 m ≈ | 17.5 m ≈ |
| Share repurchases | 0 | 22.0 k | 0 ≈ | 0 ≈ | 91.0 k | 0 | 21.4 m ≈ | 10.0 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 100 percentile of its own 2-quarter history (min 48.1, median 69.0, max 90.0; quarters with earnings only).
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 306.1 m | 412.3 m | 812.0 m |
| Revenue YoY | unavailable | +34.7% | +97.0% |
| Net income | -341.4 m | -281.9 m | -68.1 m |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | -13.24 | -10.66 | -3.22 |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | -111.5% | -68.4% | -8.4% |
| Free cash flow | -298.4 m | -253.6 m | 66.9 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 796.3 m USD
- Financial debt
- 379.0 m USD
- Net debt
- -417.3 m USD
- Equity
- 577.3 m USD
- Total assets
- 1.1 bn USD
- Debt / equity
- 0.66x
- Current ratio
- 7.85x
- ROE
- unavailable
- ROA
- -9.3%
- FCF margin
- 8.2%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 306.1 m | 412.3 m | 812.0 m | SEC (XBRL)· 03 Mar 2026verified |
| Research & development | 116.9 m | 113.9 m | 101.6 m | SEC (XBRL)· 03 Mar 2026verified |
| Operating income | -319.6 m | -257.1 m | 45.1 m | SEC (XBRL)· 03 Mar 2026verified |
| Depreciation & amortisation | 49.0 m | 48.9 m | 22.6 m | SEC (XBRL)· 03 Mar 2026verified |
| EBITDA | -270.6 m ≈ | -208.2 m ≈ | 67.7 m ≈ | SEC (XBRL)· 03 Mar 2026derived |
| Interest expense | 31.6 m | 50.0 m | 56.9 m | SEC (XBRL)· 03 Mar 2026verified |
| Pre-tax income | -341.4 m | -281.9 m | -68.1 m | SEC (XBRL)· 03 Mar 2026verified |
| Income tax | 0 | 0 | 0 | SEC (XBRL)· 03 Mar 2026verified |
| Net income | -341.4 m | -281.9 m | -68.1 m | SEC (XBRL)· 03 Mar 2026verified |
| Diluted EPS | -13.24 | -10.66 | -3.22 | SEC (XBRL)· 03 Mar 2026verified |
| Weighted average diluted shares | 34.9 m | 35.5 m | 167.2 m | SEC (XBRL)· 03 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | — | 64.0 m | 796.3 m | SEC (XBRL)· 03 Mar 2026verified |
| Receivables | — | 88.2 m | 112.1 m | SEC (XBRL)· 03 Mar 2026verified |
| Current assets | — | 215.7 m | 997.8 m | SEC (XBRL)· 03 Mar 2026verified |
| Property, plant & equipment, net | — | 67.8 m | 63.2 m | SEC (XBRL)· 03 Mar 2026verified |
| Goodwill | — | 19.3 m | 19.3 m | SEC (XBRL)· 03 Mar 2026verified |
| Total assets | — | 343.7 m | 1.1 bn | SEC (XBRL)· 03 Mar 2026verified |
| Accounts payable | — | 27.8 m | 39.2 m | SEC (XBRL)· 03 Mar 2026verified |
| Short-term debt | — | 60.1 m | 169.0 k | SEC (XBRL)· 03 Mar 2026verified |
| Long-term debt | — | 319.4 m | 378.8 m | SEC (XBRL)· 03 Mar 2026verified |
| Current liabilities | — | 165.4 m | 127.1 m | SEC (XBRL)· 03 Mar 2026verified |
| Total liabilities | — | 620.9 m | 548.4 m | SEC (XBRL)· 03 Mar 2026verified |
| Equity | -2.1 bn † | -2.5 bn † | 577.3 m † | SEC (XBRL)· 03 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | -276.1 m | -245.2 m | 83.2 m | SEC (XBRL)· 03 Mar 2026verified |
| Capex | 22.3 m | 8.4 m | 16.3 m | SEC (XBRL)· 03 Mar 2026verified |
| Free cash flow | -298.4 m ≈ | -253.6 m ≈ | 66.9 m ≈ | SEC (XBRL)· 03 Mar 2026derived |
| Investing cash flow | 214.8 m | 52.9 m | -16.3 m | SEC (XBRL)· 03 Mar 2026verified |
| Financing cash flow | 10.1 m | 200.3 m | 665.0 m | SEC (XBRL)· 03 Mar 2026verified |
| Share repurchases | 0 | 0 | 113.0 k | SEC (XBRL)· 03 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 47.9% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 9.5 bn USD
Key indicators
Coverage and freshness
Score by group
48% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 9.87 – 12.37 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E9.87 – 12.37 (Mid 11.25)4 companies used · median multiple 33.1x · quartiles 29.0x – 36.3xCDNA, DGX, LH, VCYT
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 47.9% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 9.2% | 78 (vs peers) | 13% |
| FCF conversion · Quality | 30.1% | 0 (on a fixed band) | 13% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 3.3x | 27 (on a fixed band) | 13% |
| Current ratio · Balance sheet | 6.7x | 100 (on a fixed band) | 9% |
| P/E (TTM) · Valuation | 97.6x | 17 (vs peers) | 22% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 0.3% | 4 (on a fixed band) | 17% |
| Shareholder yield (distributions) · Returns | 0.3% | 5 (on a fixed band) | 13% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet56/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality39/100 · 2/3 factors with a value
- Returns· partial5/100 · 1/2 factors with a value
- Valuation11/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
CARIS LIFE SCIENCES, INC. (CAI). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 812.0 m USD in 2025; YoY growth 97.0%; net margin 9.2%; ROE 17.2%.
The estimated value range is 9.87–12.37 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 11.25 USD, the price of 33.22 USD leaves a potential of -66.1% (value / price − 1) and a margin of safety of -195.3% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 47.9% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 9.2%
- Current ratio: 6.7x
What contradicts it
- FCF conversion: 30.1%
- Interest coverage: 3.3x
- P/E (TTM): 97.6x
- FCF yield: 0.3%
- Shareholder yield (distributions): 0.3%
- The price is above the estimated value range
Not assessed (insufficient data or a ratio without meaning): ROIC, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, EV/EBITDA, Payout ratio (FCF).
Versus the vertical median
Services-Medical Laboratories (SIC 8071) · same industry (4-digit SIC) · compared with 23 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| NTRANatera, Inc. | 56.4 bn | — | -12.5% | -7.1% | +35.9% | +64% / +599% |
| LHLabcorp Holdings Inc. | 29.9 bn | 30.2 | 11.4% | 6.9% | +7.2% | +37% / +70% |
| DGXQuest Diagnostics Inc | 28.1 bn | 25.5 | 15.2% | 9.5% | +11.8% | +35% / +86% |
| GHGuardant Health, Inc. | 22.6 bn | — | — | -38.3% | +32.9% | +55% / +570% |
| CAICaris Life Sciences, Inc. | 9.5 bn | 97.6 | 17.2% | 9.2% | +97.0% | +7% / unavailable |
| GRALGRAIL, Inc. | 6.4 bn | — | -16.1% | -236.9% | +17.2% | +30% / unavailable |
| RDNTRadNet, Inc. | 6.3 bn | — | -2.1% | -0.9% | +11.5% | −3% / +142% |
| CDNACaredx, Inc. | 4.5 bn | 35.9 | 33.0% | 25.9% | +13.8% | +380% / +784% |
| VCYTVeracyte, Inc. | 4.2 bn | 37.5 | 8.8% | 20.4% | +16.0% | +11% / +105% |
| FTREFortrea Holdings Inc. | 2.0 bn | — | -12.3% | -2.6% | +1.0% | +64% / −29% |
| PSNLPersonalis, Inc. | 1.7 bn | — | -62.1% | -147.7% | −17.7% | +47% / +932% |
| BLLNBillionToOne, Inc. | 1.3 bn | 118.4 | 30.2% | 11.3% | +100.0% | −13% / unavailable |
| CSTLCastle Biosciences, Inc. | 1.1 bn | — | -4.2% | -5.4% | +3.7% | −11% / +79% |
| FLGTFulgent Genetics, Inc. | 541.5 m | — | -8.0% | -26.0% | +13.8% | −33% / −29% |
| YDESYD Bio Limited | 492.0 m | — | -445.1% | -1,392.6% | +16.9% | −40% / unavailable |
| BDSXBiodesix, Inc. | 226.7 m | — | -540.0% | -27.0% | +24.1% | +160% / −28% |
| XGNExagen Inc. | 206.2 m | — | -113.8% | -26.6% | +19.7% | +8% / +363% |
| SERASera Prognostics, Inc. | 59.0 m | — | -49.7% | -34,866.7% | +5.2% | −39% / +4% |
| AMSAmerican Shared Hospital Services | 8.2 m | — | -7.5% | -5.8% | −0.9% | −43% / −48% |
| MDXHMdxhealth SA | 8.0 m | — | -2,440.4% | -31.1% | +19.8% | −96% / −95% |
| ACONAclarion, Inc. | 5.0 m | — | -59.0% | -10,978.5% | +65.6% | −72% / −100% |
| ADVBAdvanced Biomed Inc. | 3.5 m | 0.4 | 84.8% | 5,231.3% | unavailable | −75% / unavailable |
| BGLCBioNexus Gene Lab Corp. | 2.8 m | — | -33.7% | -82.4% | −21.9% | −79% / −90% |
| BNRBurning Rock Biotech Limited | 0 | — | -10.1% | -10.3% | +9.2% | −41% / +55% |
1- and 3-year price returns: for CAI from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 21.36 Total return -36% · Per year -36% | 37.59 Total return 13% · Per year 13% | 56.39 Total return 70% · Per year 70% |
| 3 years | 25.34 Total return -24% · Per year -9% | 49.71 Total return 50% · Per year 14% | 81.20 Total return 144% · Per year 35% |
| 5 years | 30.05 Total return -10% · Per year -2% | 65.75 Total return 98% · Per year 15% | 116.92 Total return 252% · Per year 29% |
- Exit P/E± 12.43
- Net margin± 8.70
- Annual revenue growth± 6.49
- Annual dilution± 0.73
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Aug 2026; since then the company filed 8-K (04 Nov 2026 · results), 10-Q (04 Nov 2026).
In brief
Caris Life Sciences develops and commercializes precision medicine profiling in oncology, combining next-generation sequencing, artificial intelligence and large clinico-genomic datasets. The company reported strong revenue growth in 2026, and recent launches of early detection and prognostic tests extend its offering beyond traditional tissue testing. Total revenue was 263.7 million USD in the second quarter of 2026, and 2026 guidance sits between 1.03 and 1.04 billion USD.
SWOT
Strengths
- A large clinico-genomic dataset built from comprehensive profiling of many cases, which supports algorithm development and new solutions 1.
- Strong growth in case volume and revenue in the second quarter of 2026, with improving gross margins 3.
- Partnerships with several large biopharma companies that use the company's data in research and development 1.
Weaknesses
- A history of significant net losses, though the loss in the second quarter of 2026 was close to zero 13.
- Revenue depends mainly on tissue-based profiling, which makes the company vulnerable to changes in that segment 1.
- Significant indebtedness and reliance on limited suppliers for sequencers and reagents could complicate operations 1.
Opportunities
- The launch of Caris Detect and other early detection tests could open a new market segment if clinical adoption is confirmed 23.
- Expansion into other chronic diseases such as cardiology, neurology and metabolic conditions could diversify the business 1.
- Growing adoption of blood-based tests and digital tools could support new revenue streams 2.
Risks
- Uncertain profitabilityhigh
The company cannot guarantee long-term annual GAAP profitability, and expenses rise as it invests in new solutions 1.
- Dependence on tissue profilinghigh
Most revenue comes from tissue-based profiling, so lower demand for this product could affect results 1.
- Payer reimbursementmedium
Limited broad coverage from payers could restrict access to solutions and revenue growth 1.
- LDT regulationmedium
Changes in US LDT regulation could impose new requirements on products sold in this format 1.
- Data security and compliancemedium
A cybersecurity incident or breach of privacy rules could lead to penalties and lost revenue 1.
Investment thesis
What would need to be true (bull case)
- If growth in case volume and higher average selling prices continue, revenue could meet or exceed the updated 2026 guidance 3.
- Recent launches such as Caris Detect and Caris ChromoSeq could open new market segments if they are adopted clinically 2.
- The large dataset and pharma partnerships could provide a competitive advantage that is hard to replicate 1.
What would break the thesis
What to watch
- Delivery of 2026 revenue guidance of 1.03 to 1.04 billion USD2026
- Clinical adoption and reimbursement coverage for Caris DetectQ3 2026
- Trend in gross margin and net loss in coming quartersQ3 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Aug 2026; since then the company filed 8-K (04 Nov 2026 · results), 10-Q (04 Nov 2026).
The business
Caris has built a patient-centric TechBio model that links molecular profiling with AI-driven analysis, and its data loop feeds clinical products and biopharma partnerships with companies such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech 1. In the second quarter of 2026, it launched Caris Detect for multi-cancer early detection, Caris ChromoSeq for myeloid malignancies and Caris MI Clarity, an AI-based prognostic tool using computational pathology 23.
Molecular profiling services have been the main revenue source, covering tests ordered by physicians and, to a smaller extent, research services for pharma 1. The company posted net losses in recent years, but in the second quarter of 2026 its net loss was only 0.6 million USD and operating cash flow was positive 3.
Segments
Pharma research and development services
This segment sells data access and bioinformatics services to biopharma and academic partners for target discovery and drug development. The reviewed materials do not give a separate 2026 figure for this segment, so its contribution remains largely undisclosed 12.
Early detection and digital solutions
Caris Detect, launched in the second quarter of 2026, is a blood-based WGS test for early detection of multiple cancers, and Caris MI Clarity is a digital image-based prognostic tool. Both are at an early commercial stage, and their effect on revenue is not yet quantified in the available sources 23.
Market context
Trends
- Falling NGS sequencing coststailwind
Lower costs of next-generation sequencing make molecular profiling more accessible to the healthcare system, which supports growth in test volumes 1.
- Adoption of blood-based testingtailwind
Clinical guidelines are beginning to accept complementary use of liquid and tissue biopsy, which could increase demand for products such as Caris Assure 1.
- Uncertainty in LDT regulationheadwind
Regulation of laboratory-developed tests in the United States remains uncertain, and legal changes could affect products sold in this format 1.
- Pressure on reimbursementmixed
Coverage and reimbursement by third-party payers are not assured, and pricing differences could affect margins and revenue per case 1.
Competitive position
The precision medicine industry is highly competitive and changes rapidly, with frequent technological breakthroughs, and the company acknowledges it must constantly update its solutions to stay relevant 1. Competition comes from diagnostic laboratories offering genomic testing as well as providers of technology and data to the pharma industry 1.
Caris states its advantage lies in the depth and scale of its dataset, its position as the only genomic profiling company that consistently applies WES and WTS to every eligible sample, and its combination of this data with AI, which new entrants could find difficult to replicate 12.
- Tissue and blood genomic profiling laboratories
Competitors offering NGS testing for oncology that may compete for the same ordering physicians; the reviewed sources do not name them individually.
- Multi-cancer early detection test providers
Companies developing blood-based tests for early cancer detection, a field into which Caris Detect is now entering.
- AI and data companies for drug discovery
Players providing data and analytics for pharma partnerships, competing with Caris research segment.
- Sequencing technology suppliers
Makers of next-generation sequencers influence costs and access to technology, though the sources do not name them.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A LookYahoo Finance — News · 22 Sept 2026 · EN
The latest news item in our archive is from 22 Sept 2026; the newest SEC filing is from 04 Nov 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report04 Nov 2026
- Current report04 Nov 2026Results of operations · Financial statements and exhibits
- Current report14 Sept 2026Regulation FD disclosure
- Quarterly report05 Aug 2026
- Current report05 Aug 2026Results of operations · Financial statements and exhibits
- Current report05 Jun 2026Shareholder vote
- Quarterly report08 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
- Proxy statement23 Apr 2026
- Current report02 Apr 2026Material agreement · Termination of a material agreement · Creation of a direct financial obligation
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Caris Life Sciences, Inc. · 03 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Caris Life Sciences, Inc. · 05 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Caris Life Sciences, Inc. · 05 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.